ÂÜÀòÂÒÂ×

Thomas S. Dann has a long and successful career in the business world, having held multiple executive and advisory positions since 2000. In 2004, they were appointed Director of the Maryland Venture Fund Board, Enterprise Program for the Maryland Department of Business and Economic Development. In 2010, they founded and became Managing Director of Castlehaven Advisors, LLC, a specialized provider of advisory services. Thomas S. also served as Director and Venture Partner of Global Internet Ventures, LLC and GIV Venture Partners, L.P. In 2012, they were appointed Managing Director of Equity Funds for the Maryland Venture Fund. In 2017, they joined Quidient, LLC as a Member of the Board of Advisors. In 2020, they became Director of HeMemics Biotechnologies, Inc. and in 2021, they were appointed Senior Advisor and Vice President of Legal, Strategy & Investor Relations, Corporate Secretary at Cellphire Therapeutics, Inc. Finally, in 2022, they were appointed President of MedLiquidity Corporation.

Thomas S. Dann holds a Bachelor of Arts from Stanford University and a Doctor of Law - JD from American University Washington College of Law.